Effect of 4,5-diphenyl-2-bis-(2-hydroxyethyl)aminoxazol (ditazol) on platelet aggregation, adhesiveness and bleeding time.
D000241:Adenosine / Q000494:pharmacology; D000244:Adenosine Diphosphate / Q000494:pharmacology; D000328:Adult; D000704:Analysis of Variance; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D001241:Aspirin / Q000494:pharmacology; D001777:Blood Coagulation / Q000187:drug effects*; D003094:Collagen / Q000494:pharmacology; D004176:Dipyridamole / Q000494:pharmacology; D004347:Drug Interactions; D004837:Epinephrine / Q000494:pharmacology; D000431:Ethanol / Q000494:pharmacology; D004983:Ethanolamines / Q000494:pharmacology; D006801:Humans; D008297:Male; D051379:Mice; D008875:Middle Aged; D010080:Oxazoles / Q000494:pharmacology*; D010653:Phenylbutazone / Q000494:pharmacology; D010973:Platelet Adhesiveness / Q000187:drug effects*; D011817:Rabbits; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D004983:Ethanolamines; D010080:Oxazoles; D000431:Ethanol; D000244:Adenosine Diphosphate; D004176:Dipyridamole; D003094:Collagen; D010653:Phenylbutazone; D000241:Adenosine; D001241:Aspirin; D004837:Epinephrine